KRAS and colorectal carcinoma: We already know that CRC-associated gene mutations with known clinical utilities, such as KRAS, APC, TP53, ERBB1/2, and FBXW7, may be evaluated in the CTC genome to predict accurate treatment options and interventions (Bidard et al., 2019) (Table 1).